Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 5/20 | 0.42 |
| ▸ | CA2 | P00918 | 5/20 | 0.42 |
| ▸ | CA4 | P22748 | 5/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 8/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 8/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CA6 | P23280 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2692052 | 0.94 | NPC1 (0.44) | NPC1RAB9AGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL7146270 | 0.89 | NPC1 (0.43) | NPC1RAB9AGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL2691139 | 0.86 | HTT (0.35) | NPC1RAB9AGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL3817862 | 0.84 | NPC1 (0.46) | NPC1RAB9AGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL21633940 | 0.83 | NPC1 (0.38) | NPC1RAB9AGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL5563286 | 0.81 | NPC1 (0.46) | NPC1RAB9AGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL918474 | 0.80 | CA1 (0.45) | NPC1RAB9AGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL20165714 | 0.80 | CA1 (0.45) | NPC1RAB9AGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL2302905 | 0.79 | NPC1 (0.41) | NPC1RAB9AGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL2436086 | 0.79 | NPC1 (0.41) | NPC1RAB9AGAASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117986090-A | Novel fragrances with rose scent | 西姆莱斯股份公司 | 2024-05-07 | — | — | CN | claimed |
| US-11634659-B2 | Fragrances with rose scent | SYMRISE AG (DE) | 2023-04-25 | — | — | US | claimed |
| US-20210324300-A1 | NOVEL FRAGRANCES WITH ROSE SCENT | SYMRISE AG (DE) | 2021-10-21 | — | — | US | claimed |
| EP-3826986-A1 | NOVEL ODORANTS HAVING ROSE ODOUR | Symrise AG (DE) | 2021-06-02 | — | — | EP | claimed |
| CN-112469685-A | Novel flavoring agent with rose smell | 西姆莱斯股份公司 | 2021-03-09 | — | — | CN | claimed |
| WO-2020020434-A1 | NOVEL ODORANTS HAVING ROSE ODOUR | SYMRISE AG (DE) | 2020-01-30 | — | — | WO | claimed |
| WO-2007009982-A1 | 4-ISOAMYLCYCLOHEXANONE AS A PERFUME | SYMRISE GMBH & CO. KG (DE) | 2007-01-25 | — | — | WO | claimed |
| US-20260137644-A1 | COMPOSITIONS INCLUDING CAFFEIC ACID PHENETHYL ESTER | XMK THERAPEUTICS INC. (CA) | 2026-05-21 | — | — | US | disclosed |
| EP-3826986-B1 | NOVEL ODORANTS HAVING ROSE ODOUR | SYMRISE AG (DE) | 2026-03-04 | — | — | EP | disclosed |
| EP-4199896-B1 | LIQUID PERSONAL CARE COMPOSITIONS AND METHODS FOR THE SAME | COLGATE PALMOLIVE CO (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-4629974-A1 | NOOTKATONE FOR THE TREATMENT OF GUT OR ABDOMINAL PAIN | Enveda Therapeutics, Inc. (US) | 2025-10-15 | — | — | EP | disclosed |
| EP-4629968-A1 | NOOTKATONE FOR THE TREATMENT OF PRURITUS | Enveda Therapeutics, Inc. (US) | 2025-10-15 | — | — | EP | disclosed |
| EP-4615429-A1 | COMPOSITIONS INCLUDING CAFFEIC ACID PHENETHYL ESTER | XMK Therapeutics Inc. (CA) | 2025-09-17 | — | — | EP | disclosed |
| US-20070264297-A1 | Formulated tick and insect repellent compositions | 1,4Group, Inc. | 2007-11-15 | — | — | US | disclosed |
| WO-2007009982-A1 | 4-ISOAMYLCYCLOHEXANONE AS A PERFUME | SYMRISE GMBH & CO. KG (DE) | 2007-01-25 | — | — | WO | disclosed |
| US-20060067903-A1 | Using 2-difluoromethylornithine | THE GILLETTE COMPANY, A DELAWARE CORPORATION | 2006-03-30 | — | — | US | disclosed |
| US-7015349-B2 | Reduction of hair growth | THE GILLETTE COMPANY (US) | 2006-03-21 | — | — | US | disclosed |
| US-20050244441-A1 | Cosmetic compositions | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. | 2005-11-03 | — | — | US | disclosed |
| US-5756438-A | NON-SOAP CLEANSING BAR COMPRISING ANIONIC SURFACTANT, FILLER, AND WAXY BINDER; WEAR RESISTANCE | THE ANDREW JERGENS COMPANY (US) | 1998-05-26 | — | — | US | disclosed |
| US-5691287-A | SYNTHETIC DETERGENT SODIUM COCOISETHIONATE, CETYL ALCOHOL AND BUFFER | S. C. JOHNSON & SON, INC. (US) | 1997-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060067903-A1 | Using 2-difluoromethylornithine | FGF2, FGF1, KRT18 | NPC1 1806/4885RAB9A 3392/4885GAA 3991/4885 |
| US-11634659-B2 | Fragrances with rose scent | NR1H2, DUOX2, AOX1 | NPC1 1118/4885RAB9A 3817/4885GAA 4835/4885 |
| US-20070264297-A1 | Formulated tick and insect repellent compositions | MME, FNTA, ACHE | NPC1 1167/4885RAB9A 948/4885GAA 2366/4885 |
| US-20210324300-A1 | NOVEL FRAGRANCES WITH ROSE SCENT | NR1H2, DUOX2, AOX1 | NPC1 1372/4885RAB9A 3806/4885GAA 4829/4885 |
| US-20260137644-A1 | COMPOSITIONS INCLUDING CAFFEIC ACID PHENETHYL ESTER | TFEB, CUTA, PPARG | NPC1 1145/4885RAB9A 2975/4885GAA 2152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.